Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Volume 57, Number 2, July 24, 2001
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Diav-Citrin, O.
Right arrow Articles by Ornoy, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Diav-Citrin, O.
Right arrow Articles by Ornoy, A.
Neurology 2001;57:321-324
© 2001 American Academy of Neurology
Brief Communications

Is carbamazepine teratogenic?

A prospective controlled study of 210 pregnancies Orna Diav-Citrin, MD;, Svetlana Shechtman, PhD;, Judy Arnon, PhD and Asher Ornoy, MD

From the Israeli Teratogen Information Service (Drs. Diav-Citrin, Shechtman, Arnon, and Ornoy), Laboratory of Teratology; Department of Anatomy and Cell Biology (Dr. Ornoy), Hebrew University, Hadassah Medical School; and Israeli Ministry of Health (Drs. Diav-Citrin, Shechtman, Arnon, and Ornoy), Jerusalem, Israel.

Address correspondence and reprint requests to Dr. Asher Ornoy, Department of Anatomy and Cell Biology, Hebrew University and Hadassah Medical School, PO Box 12272, Jerusalem, 91120, Israel.

The Israeli Teratogen Information Service prospectively followed up 210 pregnancies with first trimester carbamazepine exposure. Pregnancy outcome was compared with that of two overlapping controls, matched and general (n = 629), exposed to nonteratogenic agents. Our study suggests a twofold increase in the rate of major congenital anomalies (12/160 [carbamazepine] versus 18/560 [general control]; relative risk 2.24; 95% CI 1.1–4.56) and a birth weight reduction of approximately 250 g after in utero exposure to carbamazepine.




This article has been cited by other articles:


Home page
 FocusHome page
K. A. Yonkers, K. L. Wisner, Z. Stowe, E. Leibenluft, L. Cohen, L. Miller, R. Manber, A. Viguera, T. Suppes, and L. Altshuler
Management of Bipolar Disorder During Pregnancy The Postpartum Period
Focus, April 1, 2005; 3(2): 266 - 279.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
K. A. Yonkers, K. L. Wisner, Z. Stowe, E. Leibenluft, L. Cohen, L. Miller, R. Manber, A. Viguera, T. Suppes, and L. Altshuler
Management of Bipolar Disorder During Pregnancy and the Postpartum Period
Am J Psychiatry, April 1, 2004; 161(4): 608 - 620.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
L. G. Costa, L. Steardo, and V. Cuomo
Structural Effects and Neurofunctional Sequelae of Developmental Exposure to Psychotherapeutic Drugs: Experimental and Clinical Aspects
Pharmacol. Rev., March 1, 2004; 56(1): 103 - 147.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
J. Liporace and A. D'Abreu
Epilepsy and Women's Health: Family Planning, Bone Health, Menopause, and Menstrual-Related Seizures
Mayo Clin. Proc., April 1, 2003; 78(4): 497 - 506.
[Abstract] [PDF]

Home page
 JWatch PsychiatryHome page
Studies in Developmental Pathology
Journal Watch Psychiatry, August 22, 2001; 2001(822): 7 - 7.
[Full Text]